ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2380

Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy?

Yoon-Kyoung Sung1,2, Soo-Kyung Cho1,2, Soyoung Won3, Jeeseon Shim3, Dam Kim4, Ji-Young Choi1, Chan-Nam Son5, Chan-Bum Choi4, Tae-Hwan Kim6, Jae-Bum Jun6, Dae-Hyun Yoo6 and Sang-Cheol Bae1,2, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 5Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, South Korea, 6Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, drug safety, Rheumatoid arthritis (RA), treatment and tuberculosis

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Isoniazid (INH) is increasingly used in RA patients with evidence of latent tuberculosis infection (LTBI) for whom TNF inhibitor therapy is planned. The potential for hepatotoxicity of INH has been concerned in RA patients treated with DMARDs including methotrexate (MTX). However, the safety and impact of INH for RA patients on persistency of TNF inhibitors has not been known. We aimed to study the safety of INH treatment for LTBI and its impact on the persistency of TNF inhibitors

Methods: Data were extracted from medical records of RA patients who had treated with TNF inhibitor at our university hospital from December 2000 to November 2011 (REtrospective study for Safety and Efficacy of Anti-RA treatment with biologiCs, RESEARCh). Comprehensive chart reviews were undertaken on all patients, and the data for each patient consists of two components: demographic and clinical characteristics (age, sex, disease duration, disease activity, comorbidity and laboratory finding) and information related with TNF inhibitors (type of drug, history of DMARDs before starting TNF inhibitor, concomitant medication andtreatment period).

 A total 312 patients aged 18 years old or older were enrolled in this study, and among them 96 patients (30.9%) experienced INH treatment for LTBI. The occurrences of LFT abnormality were evaluated in both patients with and without INH treatment.Then Kaplan-Meier curve andCox proportional hazard analysis were used to evaluate its impact on persistency of TNF inhibitors

Results: There was no difference in demographic and clinical features in both groups except the frequency of MTX use (83.3% in INH treatment group and 72.2% in INH non-user group, P=0.049). The LFT abnormality was more commonly happened in patients treated with INH than those without INH treatment (20.8% vs. 8.8%, P=0.005). This increased risk for hepatotoxicity by INH treatment was persistent after adjusting covariates including MTX use in multivariate regression analysis (OR 3.18, 95% CI 1.48-6.84). However, the persistent rate of TNF inhibitors during 5 years using Kaplan-Meier curve was not different between two groups with and without INH treatment (49.4% vs. 54.6%, p=0.79 in log-rank test). INH treatment for LTBI was not associated with discontinuation of TNF inhibitors in Cox proportional hazard model (HR 1.02, 95%CI 0.66-1.58).

Conclusion: INH treatment for LTBI in RA patients who started TNF inhibitors is associated with the occurrence of LFT abnormality. However, it does not affect the persistency of TNF inhibitors.


Disclosure:

Y. K. Sung,
None;

S. K. Cho,
None;

S. Won,
None;

J. Shim,
None;

D. Kim,
None;

J. Y. Choi,
None;

C. N. Son,
None;

C. B. Choi,
None;

T. H. Kim,
None;

J. B. Jun,
None;

D. H. Yoo,
None;

S. C. Bae,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-isoniazid-treatment-for-ltbi-safe-for-ra-patients-with-tnf-inhibitor-therapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology